– POTENTIAL TO TARGET GPRC5D IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER BCMA-TARGETED THERAPY Emeryville, California, March 27, 2019 – Eureka Therapeutics, Inc., a clinical stage
EMERYVILLE, California, February 11, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong
EMERYVILLE, California, January 30, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced that the U.S. Food
–NEW DATA FROM MULTIPLE CAR-T PROGRAMS IN MULTIPLE MYELOMA UTILIZING EUREKA’S BINDING DOMAINS –BCMA/MULTIPLE MYELOMA CAR-T PROGRAM LICENSED TO JUNO THERAPEUTICS (NOW CELGENE) –UPDATED DATA
EMERYVILLE, California, November 21, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
–ONE COMPLETE RESPONSE (CR) OBSERVED IN PATIENT WITH METASTATIC LIVER CANCER –COMPANY EXPECTS TO INITIATE MULTICENTER PHASE 1 U.S. CLINICAL TRIALS IN 2019 EMERYVILLE, California,
EMERYVILLE, CA, USA, August 30, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
EMERYVILLE, CA, USA, August 16, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
EMERYVILLE, CA, USA , July 17, 2018 – Eureka Therapeutics Inc. announced today that Boehringer Ingelheim has elected to exercise an option for the exclusive
Emeryville, California, July 16, 2018 – Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.